Selected References

Hormone Replacement Therapy for the Primary Prevention of Chronic Diseases

Prepared by C. N. Wathen, D. S. Feig, J. W. Feightner, B. L. Abramson, A. M. Cheung, with the Canadian Task Force on Preventive Health Care

These recommendations were finalized by the Task Force in February 2003.

  1. Feig DS. Prevention of osteoporotic fractures in women by estrogen replacement therapy. In: Canadian Task Force on the Periodic Health Examination. Canadian guide to clinical preventive health care. Ottawa: Health Canada; 1994. p. 620-31.
  2. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality amongpostmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
  3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63
  4. Barrett-Connor E. Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases. Am J Med 1993;95(Suppl 5A):40S-3S.
  5. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
  6. Cheung AM, Proctor WR, Stewart DE, with the Canadian Task Force on Preventive Health Care. The effect of hormone replacement therapy on cancer in postmenopausal women: systematic review [CTFPHC Technical Report no 03-3]. London (ON): The Task Force; 2003.
  7. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WE et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-90.
  8. WHO Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
  9. Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980; 55(6):732-38.
  10. Abramson B, with the Canadian Task Force on Preventive Health Care. Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease. Systematic Review and Recommendations. CTFPHC Technical Report no 03-2. London (ON): The Task Force; 2003.
  11. Cheung AM, Feig DS, Kapral MK, Diaz-Granados N, Dodin S, with the Canadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: Systematic review & recommendations. CTFPHC Technical Report no 03-1. London (ON): The Task Force; 2003.
  12. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288 (7): 872-81.
  13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33.
  14. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291 (14): 1704-12.
  15. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137(10):834-9.
  16. American College of Obstetricians and Gynecologists. Questions and answers on hormone therapy [press release]. Washington: The College; August 2002. Available: www.acog.org/from_home/publications/press_releases/nr08-30-02.cfm (accessed 2004 Mar 03).
  17. North American Menopausal Society. Estrogen and progestogen use in peri- and post-menopausal women: September 2003 position statement from the North American Menopause Society. Cleveland: The Society; 2003. Available: www.menopause.org/aboutmeno/HTpositionstatement.pdf (accessed 2004 Mar 3).
  18. Benefits and risks of combined (estrogen and progestin) hormone replacement therapy. In: It's Your Health. Ottawa: Health Canada; updated 2004 Jan 21. Available: www.hc-sc.gc.ca/english/iyh/medical/estrogen.html (accessed 2004 Mar 3).
  19. US Food and Drug Administration (FDA). FDA approves new labeling and provides new advice to postmenopausal women who use or who are considering using estrogen and estrogen with progestin [FDA Fact Sheet]. Washington: FDA; 2003 Jan 8. Available: www.fda.gov/oc/factsheets/WHI.html (accessed 2004 Mar 3).
  20. Abramson BL, Derzko C, Lalonde A, Reid R, Turek M, Weilgosz A. Hormone replacement therapy and cardiovascular disease: a joint statement from the Heart and Stroke Foundation of Canada, the Society of Obstetricians and Gynaecologists of Canada and the Canadian Cardiovascular Society. Can J Cardiol 2000;18(7):723-4.
  21. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349(6):523-34.
  22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
  23. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343(8):522-9.
  24. Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004; 170 (9): 1388-9.
  25. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum in Lancet 2003;362:1160]. Lancet 2003;362:419-27.
  26. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
  27. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10(4):253-60.
  28. Tavani A, Ricci E, La Vecchia C, Surace M, Benzi G, Parazzini F, et al. Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 2000;29:799-802.
  29. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
  30. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
  31. Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001; 12: 337-41.
  32. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-23.
  33. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
  34. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
  35. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.
  36. Cheung AM, Feig D, Kapral M, Diaz-Granados N, Dodin S, and the Canadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women. Recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ. In press.
  37. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 83 (1): 5-11.
  38. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62.
  39. Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T; HERS Research Group. Postmenopausal hormones and incontinence: the Heart and Estrogen/ Progestin Replacement Study. Obstet Gynecol 2001; 97 (1): 116-20.
  40. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348(19):1-16.
  41. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289 (20): 2663-72.
  42. Beaudet MP, Walop W, Le Petit C. Characteristics of women on hormone replacement therapy. Health Rep 1997; 9(2). Ottawa: Statistics Canada. Cat no 82-003-XPB.
  43. Kaufert P, Boggs PP, Ettinger B, Woods NF, Utian WH. Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey. Menopause 1998;5:197-202.
  44. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4 (1): 58-74.